Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mallesh, Pandrala"'
Autor:
Mausam Kalita, Jun Hyung Park, Renesmee Chenting Kuo, Samira Hayee, Sara Marsango, Valentina Straniero, Israt S. Alam, Angelie Rivera-Rodriguez, Mallesh Pandrala, Mackenzie L. Carlson, Samantha T. Reyes, Isaac M. Jackson, Lorenzo Suigo, Audrey Luo, Sydney C. Nagy, Ermanno Valoti, Graeme Milligan, Frezghi Habte, Bin Shen, Michelle L. James
Publikováno v:
JACS Au, Vol 3, Iss 12, Pp 3297-3310 (2023)
Externí odkaz:
https://doaj.org/article/809eacb49e1c4dafa4e7d776f1a34874
Autor:
Mark Mercola, Sanjay V. Malhotra, Ravindra Majeti, Matthew H. Porteus, Ronglih Liao, Volker Wiebking, Isabel Morgado, Yusuke Nakauchi, Saloni Gupta, Prashila Amatya, Michelle M. Vu, Dries A.M. Feyen, Ricardo Serrano, Wenqi Li, Arpit Dheeraj, Mallesh Pandrala, Dhanir Tailor, Arne A.N. Bruyneel, Anna P. Hnatiuk
Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c844dc6c35715db1639cea0b4e417f7
https://doi.org/10.1158/0008-5472.22431758
https://doi.org/10.1158/0008-5472.22431758
Autor:
Mark Mercola, Sanjay V. Malhotra, Ravindra Majeti, Matthew H. Porteus, Ronglih Liao, Volker Wiebking, Isabel Morgado, Yusuke Nakauchi, Saloni Gupta, Prashila Amatya, Michelle M. Vu, Dries A.M. Feyen, Ricardo Serrano, Wenqi Li, Arpit Dheeraj, Mallesh Pandrala, Dhanir Tailor, Arne A.N. Bruyneel, Anna P. Hnatiuk
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8813de7c26c00813e4b1aeccf4913459
https://doi.org/10.1158/0008-5472.22431764.v1
https://doi.org/10.1158/0008-5472.22431764.v1
Autor:
Mark Mercola, Sanjay V. Malhotra, Ravindra Majeti, Matthew H. Porteus, Ronglih Liao, Volker Wiebking, Isabel Morgado, Yusuke Nakauchi, Saloni Gupta, Prashila Amatya, Michelle M. Vu, Dries A.M. Feyen, Ricardo Serrano, Wenqi Li, Arpit Dheeraj, Mallesh Pandrala, Dhanir Tailor, Arne A.N. Bruyneel, Anna P. Hnatiuk
Small molecule tyrosine kinase inhibitors (TKI) have revolutionized cancer treatment and greatly improved patient survival. However, life-threatening cardiotoxicity of many TKIs has become a major concern. Ponatinib (ICLUSIG) was developed as an inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d40ba8736ba377c4c66ede63656f56e
https://doi.org/10.1158/0008-5472.c.6513977.v1
https://doi.org/10.1158/0008-5472.c.6513977.v1
Autor:
Anna P. Hnatiuk, Arne A.N. Bruyneel, Dhanir Tailor, Mallesh Pandrala, Arpit Dheeraj, Wenqi Li, Ricardo Serrano, Dries A.M. Feyen, Michelle M. Vu, Prashila Amatya, Saloni Gupta, Yusuke Nakauchi, Isabel Morgado, Volker Wiebking, Ronglih Liao, Matthew H. Porteus, Ravindra Majeti, Sanjay V. Malhotra, Mark Mercola
Publikováno v:
Cancer Research. 82:2777-2791
Small molecule tyrosine kinase inhibitors (TKI) have revolutionized cancer treatment and greatly improved patient survival. However, life-threatening cardiotoxicity of many TKIs has become a major concern. Ponatinib (ICLUSIG) was developed as an inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6df831a95b4efdb29819b42ec16bf55f
https://doi.org/10.1158/0008-5472.can-21-3652
https://doi.org/10.1158/0008-5472.can-21-3652
Publikováno v:
Journal of medicinal chemistry. 65(16)
Development of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogene constitutes an effective approach for the treatment of chronic myeloid leukemia (CML) and/or acute lymphoblastic leukemia. However, currently available inhibitors are lim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4456e11a6c11c75f590868174b96fd2d
https://pubmed.ncbi.nlm.nih.gov/35944901
https://pubmed.ncbi.nlm.nih.gov/35944901
Autor:
Anna Hnatiuk Hnatiuk, Arne Bruyneel, Dhanir Taylor, Mallesh Pandrala, Ricardo Serrano, Dries Feyen, Yusuke Nakauchi, Michelle Vu, Prashila Amatya, Ravindra Majeti, Sanjay Malhotra, Mark Mercola
Publikováno v:
Circulation Research. 131
Introduction: Ponatinib is one of the most cardiotoxic Tyrosine Kinase Inhibitors (TKIs), but continues to be used in clinical practice as it is the only TKI effective against the most common ABL T315I mutation in Chronic Myeloid Leukemia (CML). Long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2341257a29675072fdc9a5b586a5d790
https://doi.org/10.1161/res.131.suppl_1.p3105
https://doi.org/10.1161/res.131.suppl_1.p3105
Autor:
Binil Eldhose, Katherine Beck, Cyrus Eghtedari, Gartrell C. Bowling, Mallesh Pandrala, Sanjay V. Malhotra, Xiaofeng A. Su, Albert Dobi
Publikováno v:
Cancer Research. 83:4868-4868
Introduction: Prostate cancer (PCa) is the second leading cause of cancer deaths among men in the United States. Approximately 50% of patients with PCa harbor an oncogenic TMPRRS2- ERG gene fusion in their primary tumor and 35% of patients with metas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f115103bdb1a314580d67be50eb77f39
https://doi.org/10.1158/1538-7445.am2023-4868
https://doi.org/10.1158/1538-7445.am2023-4868
Autor:
Shaghayegh, Jahanbani, Paige S, Hansen, Lisa K, Blum, Effie E, Bastounis, Nitya S, Ramadoss, Mallesh, Pandrala, Jessica Marie, Kirschmann, Grace Sisemore, Blacker, Zelda Z, Love, Irving L, Weissman, Fahimeh, Nemati, Michal Caspi, Tal, William H, Robinson
Publikováno v:
Clinical Immunology. 246:109180
Borrelia burgdorferi (Bb) infection causes Lyme disease, for which there is need for more effective therapies. Here, we sequenced the antibody repertoire of plasmablasts in Bb-infected humans. We expressed recombinant monoclonal antibodies (mAbs) rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0204a0507ece940bc600dd481b31796c
https://doi.org/10.1016/j.clim.2022.109180
https://doi.org/10.1016/j.clim.2022.109180
Autor:
Rayhaneh Afjei, Negar Sadeghipour, Sukumar Uday Kumar, Mallesh Pandrala, Vineet Kumar, Sanjay V. Malhotra, Tarik F. Massoud, Ramasamy Paulmurugan
Publikováno v:
Cancers; Volume 14; Issue 24; Pages: 6120
TP53 tumor suppressor gene is a commonly mutated gene in cancer. p53 mediated senescence is critical in preventing oncogenesis in normal cells. Since p53 is a transcription factor, mutations in its DNA binding domain result in the functional loss of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15731911b87bec45628535fe5d058301
https://doi.org/10.3390/cancers14246120
https://doi.org/10.3390/cancers14246120